On February 17, 2026, Superstring Capital Management reported selling 345,869 shares of Terns Pharmaceuticals (NASDAQ:TERN) ...

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of blood cancers such as Chronic Lymphocytic Leukemia The post Women’s Health ...

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and ...

Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with ...

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in ...

Two years after first sharing her story, young cancer survivor Ellie Mai Murphy from Glasson says she is now focusing on ...